Evaluating The Acceptability and Uptake of Pre-Exposure Prophylaxis (PrEP) for Adolescent Women in The Deep South

Not Applicable

Withdrawn

• Conditions: Adolescent Behavior; HIV/AIDS; PrEP
• Interventions: Other: Telehealth Coaching

• Registration Number: NCT03897725
• Lead Sponsor: University of Alabama at Birmingham

Brief Summary

This project is designed to 1) develop a PrEP implementation plan for a general adolescent clinic. Investigators will develop a replicable implementation plan for providing PrEP to adolescents in a primary care setting; and 2) Determine the acceptability and preliminary effectiveness of a telehealth intervention to promote adherence in adolescents.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-03-28
• Study First Submitted QC: 2019-03-28
• Study First Posted: 2019-04-01
• Study Start: 2020-12-01
• Status Verified: 2021-11
• Last Update Submitted: 2021-11-05
• Last Update Posted: 2021-11-12
• Primary Completion: 2022-09-30
• Study Completion: 2022-09-30

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

• Females between 15 to 21 years old
• Established patients at the Adolescent Health Center
• HIV negative

Read More

Exclusion Criteria

• HIV positive patients
• patients weighing less than 35kg
• patients with creatinine clearance <60 ml/min
• patients with documented osteopenia or osteoporosis or history of pathologic fractures
• patients with previous allergic reactions to either emtricitabine or tenofovir
• patients who are on post-exposure prophylaxis for HIV (they can become eligible after completion of therapy)
• patients with hepatic impairment
• For patients who become pregnant, they may be able to continue on PrEP after a discussion with their obstetrics/gynecology (OB/GYN) provider.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Telehealth Intervention	Telehealth Coaching	Study participants will be randomized into either the control or experimental group. Participants in the intervention group will receive routine care which will follow the schedule from previous adolescent PrEP studies where participants are recommended to follow up at 4, 8, and 12 weeks and then every 3 months following initiation of PrEP. This group will also receive SMS texting every 4 weeks between in-person visits (weeks 16, 20, 28,32, 40, 44) reminding them to pick up their medication. The experimental group will also be seen in follow up every month for the first 3 months and then spaced out to visits every 3 months. The SMS texting will occur every 4 weeks between in-person visits, the experimental group will also have 2 tele-health visits (which will be conducted within a participant's home using an app) that will occur every 4 weeks between each of the traditional in-person visits to provide more frequent monitoring and counseling regarding adherence.

Primary Outcome Measures

Name	Time	Method
Adherence to PrEP	1 year	Retention of adolescent females in PrEP care (attendance at follow-up visits) and adherence to emtricitabine/tenofovir evidenced by dried blood spot sampling

Trial Locations

Locations (1)

William A. Daniel Adolescent Health Center; 🇺🇸 Birmingham, Alabama, United States